Biotechnology. Disease group invests in do-it-yourself drugs
Marshall, E.
Science 288(5472): 1715-1717
2000
ISSN/ISBN: 0036-8075 PMID: 10877679 Document Number: 515308
Document emailed within 1 workday
Related Documents
Brandsma, M.; van Ommen, G.-J.B.; Wijmenga, C.; Kiemeney, L.A. 2010: Dutch government invests in existing biobanks Nederlands Tijdschrift Voor Geneeskunde 154: A2825Kozulitsyna, T.I.; Kozlova, N.V. 1976: Effectiveness of the drugs of streptomycin group in experimental studies on albino mice infected with Mycobacterium tuberculosis resistant to these drugs Problemy Tuberkuleza 9: 70-74
Bodick, N.; Forette, F.; Hadler, D.; Harvey, R.J.; Leber, P.; McKeith, I.G.; Riekkinen, P.J.; Rossor, M.N.; Scheltens, P.; Shimohama, S.; Spiegel, R.; Tanaka, S.; Thal, L.J.; Urata, Y.; Whitehouse, P.; Wilcock, G. 1997: Protocols to demonstrate slowing of Alzheimer disease progression. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. The Disease Progression Sub-Group Alzheimer Disease and Associated Disorders 11 Suppl. 3: 50-53
1995: Control of meningococcal disease: guidance for consultants in communicable disease control. PHLS Meningococcal Infections Working Group and Public Health Medicine Environmental Group Communicable disease report. CDR review 5(13): R189-R195
Gohlke-Bärwolf, C.; Acar, J.; Oakley, C.; Butchart, E.; Burckhart, D.; Bodnar, E.; Hall, R.; Delahaye, J.P.; Horstkotte, D.; Krémer, R. 1995: Guidelines for prevention of thromboembolic events in valvular heart disease. Study Group of the Working Group on Valvular Heart Disease of the European Society of Cardiology European Heart Journal 16(10): 1320-1330
Heim, M.; Bory, M.; Ardissone, J.P.; Rivière, D.; Faure, M.H.; Sappa, P.; Bernard, F.; Simonin, R. 1990: Minimal lipid anomalies in a group of men with early coronary disease compared to a control group Annales de Cardiologie et d'Angeiologie 39(1): 13-15
Vitali, C.; Bencivelli, W.; Isenberg, D.A.; Smolen, J.S.; Snaith, M.L.; Sciuto, M.; Neri, R.; Bombardieri, S. 1992: Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE Clinical and Experimental Rheumatology 10(5): 541-547
Pedich, M.; Reperowicz-Iszczuk, J.; Maślińska, T. 1975: Effects of washed group O erythrocytes suspended in 5% albumin administered in ABO group-related hemolytic disease of the newborn Pediatria Polska 50(8): 1023-1027
Mielens, Z.E.; Connolly, K.; Stecher, V.J. 1985: Effect of disease modifying antirheumatic drugs and nonsteroidal antiinflammatory drugs upon cellular and fibronectin responses in a pleurisy model Journal of Rheumatology 12(6): 1083-1087
Thomson, T.D.; Quay, J.F.; Webber, J.A. 1984: Cephalosporin group of antimicrobial drugs Journal of the American Veterinary Medical Association 185(10): 1109-1114
Ninnemann, A.; Stuart, G.L. 2013: The NBOMe series: a novel, dangerous group of hallucinogenic drugs Journal of studies on alcohol and drugs 74(6): 977-978
Verstraete, M. 1978: The interaction between drugs and oral anticoagulants of the coumarin group La Semaine des Hopitaux: Organe Fonde Par l'Association d'Enseignement Medical des Hopitaux de Paris 54(13-16): 505-508
Chichkanov, G.G.; Tsorin, I.B.; Kirsanova, G.Iu.; Berdiaev, S.Iu.; Khorunzhił, V.A. 1997: Derivatives of 2-mercaptobenzimidazole--a new group of specific bradycardic drugs Eksperimental'naia i Klinicheskaia Farmakologiia 60(3): 23-26
Chérin, P.; Gherardi, R.K. 1998: Emergence of a new entity, the macrophagic myofasciitis. GERMMAD Study Group of the French Association Against Myopathies. Study and Research Group on Acquired Dysimmunity-related Muscle Disease Revue du Rhumatisme 65(10): 541-542
Bachmann, G.W. 1972: Beta blockaders, a new group of drugs. Present-day problems of their administration Die Medizinische Welt 23(26): 953-957
Kitamura, J.; Mori, H.; Sugie, S.; Kawai, K. 1985: Genetic toxicity of several antihypertensive drugs possessing a hydrazine group Research Communications in Chemical Pathology and Pharmacology 49(3): 415-422
Laine, M.; Lehtonen, L.; Nieminen, M.S. 2000: Calcium sensitizers--a new group of drugs that increase myocardium contractility Duodecim; Laaketieteellinen Aikakauskirja 116(20): 2181-2183
Rushchak, V.A. 1971: Use of drugs of secondary group in complex therapy of children with chronic tuberculosis Pediatriia Akusherstvo i Ginekologiia 2: 24-25
Niitani, H.; Fukuoka, M.; Furuse, K.; Kudoh, S.; Kurita, Y.; Ohnoshi, T.; Saijoh, N. 1997: New drugs for the treatment of lung cancer. the Tokyo Cooperative Oncology Group Gan to Kagaku Ryoho. Cancer and ChemoTherapy 24(Suppl 1): 117-119
Banerjee, S.; Guha, S.K. 2009: RISUG: a potential candidate for the entry inhibitor group of antiretroviral drugs Medical Hypotheses 73(2): 150-152